Mylan’s Pay for CEO Bresch Grates on Lawmakers, Many Investors

Mylan NV Chief Executive Officer Heather Bresch was lambasted at a congressional hearing this week for taking home tens of millions of dollars as the company raised the price on its EpiPen allergy shot. Some investors have been critical of Mylan’s executive compensation for years. While the drugmaker touts “strong support” for its executive pay program in regulatory filings, votes cast by shareholders tell a different story. At least 30 percent of investors have voted against the program in every election on the matter since 2011. That’s the worst streak of results among companies in Mylan’s compensation peer group, according to data compiled by Bloomberg.

filed under: Uncategorised

0 thoughts on “Mylan’s Pay for CEO Bresch Grates on Lawmakers, Many Investors”

Comments are closed.